<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We reviewed the clinical features, treatment, and outcome of 100 children with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>), and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) associated with complete <z:mp ids='MP_0004026'>monosomy</z:mp> 7 (-7) or deletion of the long arm of chromosome 7 (7q-) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with therapy-induced disease were excluded </plain></SENT>
<SENT sid="2" pm="."><plain>The morphologic diagnoses according to modified FAB criteria were: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 72 (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) in 11, RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in eight, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) in 10, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> in 43), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in 28 </plain></SENT>
<SENT sid="3" pm="."><plain>The median age at presentation was 2.8 years (range 2 months to 15 years), being lowest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> (1.1 year) </plain></SENT>
<SENT sid="4" pm="."><plain>Loss of chromosome 7 as the sole cytogenetic abnormality was observed in 75% of those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> compared with 32% of those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Predisposing conditions (including familial <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were found in 20% </plain></SENT>
<SENT sid="6" pm="."><plain>Three-year survival was 82% in RA, 63% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 45% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>, 34% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 8% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Children with -7 alone had a superior survival than those with other cytogenetic abnormalities: this was solely due to a better survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (3-year survival 56 vs 24%) </plain></SENT>
<SENT sid="8" pm="."><plain>The reverse was found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (3-year survival 13% in -7 alone vs 44% in other cytogenetic groups) </plain></SENT>
<SENT sid="9" pm="."><plain>Stable disease for several years was documented in more than half the patients with RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Patients with RA, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> treated with bone marrow transplantation (BMT) without prior chemotherapy had a 3-year survival of 73% </plain></SENT>
<SENT sid="11" pm="."><plain>The morphologic diagnosis was the strongest prognostic factor </plain></SENT>
<SENT sid="12" pm="."><plain>Only patients with a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> fitted what has previously been referred to as the <z:mp ids='MP_0004026'>monosomy</z:mp> 7 syndrome </plain></SENT>
<SENT sid="13" pm="."><plain>Our data give no support to the concept of <z:mp ids='MP_0004026'>monosomy</z:mp> 7 as a distinct syndrome </plain></SENT>
</text></document>